Perspective

Challenges and opportunities for translating medical microdevices: insights from the programmable bio-nano-chip

Department of Bioengineering, Rice University, Houston, TX, USA

Search for more papers by this author

Glennon Simmons

Department of Biomaterials, New York University, New York, NY, USA

Search for more papers by this author

John T McDevitt

*Author for correspondence:

E-mail Address: mcdevitt@nyu.edu

Department of Bioengineering, Rice University, Houston, TX, USA

Department of Biomaterials, New York University, New York, NY, USA

Department of Chemistry, Rice University, Houston, TX, USA

Search for more papers by this author

Published Online:13 Apr 2016https://doi.org/10.4155/bio-2015-0023

View article

Abstract

This perspective highlights the major challenges for the bioanalytical community, in particular the area of lab-on-a-chip sensors, as they relate to point-of-care diagnostics. There is a strong need for general-purpose and universal biosensing platforms that can perform multiplexed and multiclass assays on real-world clinical samples. However, the adoption of novel lab-on-a-chip/microfluidic devices has been slow as several key challenges remain for the translation of these new devices to clinical practice. A pipeline of promising medical microdevice technologies will be made possible by addressing the challenges of integration, failure to compete with cost and performance of existing technologies, requisite for new content, and regulatory approval and clinical adoption.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Noyce R, Hoff M. A history of microprocessor development at Intel. IEEE Micro 1(1), 8–21 (1981).
Google Scholar
2 Becker H. One size fits all? Lab Chip 10(15), 1894–1897 (2010).
Medline CASGoogle Scholar
3 Whitesides GM. The origins and the future of microfluidics. Nature 442(7101), 368–373 (2006).
Medline CASGoogle Scholar
4 Manz A, Graber N, Widmer HM. Miniaturized total chemical analysis systems: a novel concept for chemical sensing. Sensors Actuat. B 1(1–6), 244–248 (1990).
CASGoogle Scholar
5 Harrison DJ, Fluri K, Seiler K, Fan Z, Effenhauser CS, Manz A. Micromachining a miniaturized capillary electrophoresis-based chemical analysis system on a chip. Science 261(5123), 895–897 (1993).
Medline CASGoogle Scholar
6 Yager P, Edwards T, Fu E et al. Microfluidic diagnostic technologies for global public health. Nature 442(7101), 412–418 (2006).
Medline CASGoogle Scholar
7 Chin C, Chin S, Laksanasopin T, Sia S. Low-cost microdevices for point-of-care testing. In: Point-of-Care Diagnostics on a Chip. Issadore D, Westervelt RM (Eds), Springer, Berlin–Heidelberg, 3–21 (2013).
Google Scholar
8 Yetisen AK, Akram MS, Lowe CR. Paper-based microfluidic point-of-care diagnostic devices. Lab Chip 13(12), 2210–2251 (2013).
Medline CASGoogle Scholar
9 Martinez AW, Phillips ST, Butte MJ, Whitesides GM. Patterned paper as a platform for inexpensive, low volume, portable bioassays. Angew. Chem. Int. Ed. Engl. 46(8), 1318–1320 (2007).
Medline CASGoogle Scholar
10 Cheng C-M, Martinez AW, Gong J et al. Paper-based ELISA. Angew. Chem. Int. Ed. Engl. 49(28), 4771–4774 (2010).
Medline CASGoogle Scholar
11 Martinez AW, Phillips ST, Whitesides GM, Carrilho E. Diagnostics for the developing world: microfluidic paper-based analytical devices. Anal. Chem. 82(1), 3–10 (2010).
Medline CASGoogle Scholar
12 Martinez AW, Phillips ST, Carrilho E, Thomas SW, Sindi H, Whitesides GM. Simple telemedicine for developing regions: camera phones and paper-based microfluidic devices for real-time, off-site diagnosis. Anal. Chem. 80(10), 3699–3707 (2008).
Medline CASGoogle Scholar
13 Affymetrix, Inc. www.affymetrix.com.
Google Scholar
14 Luminex Corporation. www.luminexcorp.com.
Google Scholar
15 Becker H. Hype, hope and hubris: the quest for the killer application in microfluidics. Lab Chip 9(15), 2119–2122 (2009).•• Describes killer applications as it applies to the field of microfluidics
Medline CASGoogle Scholar
16 Abbott Point of Care Inc. www.abbottpointofcare.com.
Google Scholar
17 Clark TJ, McPherson PH, Buechler KF. The Triage cardiac panel: cardiac markers for the Triage system. Point of Care 1(1) (2002).
Google Scholar
18 Yiğitbaşı T. Multiplex immunoassay and bead based multiplex. In: Trends in Immunolabelled and Related Techniques. Abuelzein E (Ed.). InTech, Rijeka, Croatia, 351–360 (2012).
Google Scholar
19 Mohammed MI, Haswell S, Gibson I. Lab-on-a-chip or chip-in-a-lab: challenges of commercialization lost in translation. Procedia Technol. 20, 54–59 (2015).
Google Scholar
20 Chin CD, Linder V, Sia SK. Commercialization of microfluidic point-of-care diagnostic devices. Lab Chip 12(12), 2118–2134 (2012).•• Review of the commercialization of microfluidic/LOC devices with a focus on point-of-care (POC) applications.
Medline CASGoogle Scholar
21 Becker H. Lost in translation. Lab Chip 10(7), 813–815 (2010).
Medline CASGoogle Scholar
22 Becker H. Mind the gap! Lab Chip 10(3), 271–273 (2010).
Medline CASGoogle Scholar
23 McDevitt JT, McRae MP, Simmons GW, Christodoulides N. Programmable bio-nano-chip system: a flexible diagnostic platform that learns. J. Biosens. Bioelectron. 6, e137 (2015).• Proposes four major barriers to the clinical translation of LOC devices.
MedlineGoogle Scholar
24 Jokerst JV, Jacobson JW, Bhagwandin BD, Floriano PN, Christodoulides N, McDevitt JT. Programmable nano-bio-chip sensors: analytical meets clinical. Anal. Chem. 82(5), 1571–1579 (2010).
Medline CASGoogle Scholar
25 Chou J, Wong J, Christodoulides N, Floriano P, Sanchez X, McDevitt J. Porous bead-based diagnostic platforms: bridging the gaps in healthcare. Sensors 12(11), 15467–15499 (2012).
MedlineGoogle Scholar
26 Shadfan BH, Simmons AR, Simmons GW et al. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prev. Res. 8(1), 37–48 (2015).
Medline CASGoogle Scholar
27 Jokerst JV, Chou J, Camp JP et al. Location of biomarkers and reagents within agarose beads of a programmable bio-nano-chip. Small 7(5), 613–624 (2011).
Medline CASGoogle Scholar
28 Jokerst JV, McDevitt JT. Programmable nano-bio-chips: multifunctional clinical tools for use at the point-of-care. Nanomedicine 5(1), 143–155 (2009).
MedlineGoogle Scholar
29 Weigum SE, Floriano PN, Christodoulides N, McDevitt JT. Cell-based sensor for analysis of EGFR biomarker expression in oral cancer. Lab Chip 7(8), 995–1003 (2007).
Medline CASGoogle Scholar
30 Christodoulides N, De La Garza R II, Simmons GW et al. Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids. Drug Alcohol Depend. 153, 306–313 (2015).
Medline CASGoogle Scholar
31 McRae MP, Simmons GW, Wong J et al. Programmable bio-nano-chip system: a flexible point-of-care platform for bioscience and clinical measurements. Lab Chip 15(20), 4020–4031 (2015).•• Describes the p-BNC system in detail and provides design rationale for the fully integrated biosensing platform.
Medline CASGoogle Scholar
32 Christodoulides N, Pierre FN, Sanchez X et al. Programmable bio-nanochip technology for the diagnosis of cardiovascular disease at the point-of-care. Methodist De Bakey Cardiovasc. J. 8(1), 6–12 (2012).
MedlineGoogle Scholar
33 Becker H. It's the economy. Lab Chip 9(19), 2759–2762 (2009).• Discusses economies of scale for microfluidic devices and strategies to reduce manufacturing costs.
Medline CASGoogle Scholar
34 Dittrich PS, Tachikawa K, Manz A. Micro total analysis systems: latest advancements and trends. Anal. Chem. 78(12), 3887–3908 (2006).
Medline CASGoogle Scholar
35 Mukhopadhyay R. Microfluidics: on the slope of enlightenment. Anal. Chem. 81(11), 4169–4173 (2009).
Medline CASGoogle Scholar
36 Kelley SO, Mirkin CA, Walt DR, Ismagilov RF, Toner M, Sargent EH. Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. Nat. Nanotechnol. 9(12), 969–980 (2014).
Medline CASGoogle Scholar
37 Simmons GW, McRae MP, Shadfan B et al. Programmable bio-nano-chip system: an ultra-flexible platform for bioscience and clinical measurements. Proceedings of the 18th International Conference on Miniaturized Systems for Chemistry and Life Sciences (MicroTAS 2014), 2059–2063 (26–30 October 2014).
Google Scholar
38 Floriano PN, Christodoulides N, Miller CS et al. Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin. Chem. 55(8), 1530–1538 (2009).
Medline CASGoogle Scholar
39 Mukhopadhyay R. When PDMS isn't the best. Anal. Chem. 79(9), 3248–3253 (2007).
Medline CASGoogle Scholar
40 Vitzthum F, Behrens F, Anderson NL, Shaw JH. Proteomics: from basic research to diagnostic application. A review of requirements & needs. J. Proteome Res. 4(4), 1086–1097 (2005).
Medline CASGoogle Scholar
41 Zhang Z. An in vitro diagnostic multivariate index assay (IVDMIA) for ovarian cancer: harvesting the power of multiple biomarkers. Rev. Obstetr. Gynecol. 5(1), 35–41 (2012).•• The first IVDMIA of protein biomarkers cleared by the US FDA.
MedlineGoogle Scholar
42 US FDA. Draft guidance for industry, clinical laboratories, and FDA staff: in vitro diagnostic multivariate index assays. (US Department of Health and Human Services, 1–15 (2007). www.fda.gov/downloads/MedicalDevices/…/ucm071455.pdf.
Google Scholar
43 Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129(3), e28–e292 (2014).
MedlineGoogle Scholar
44 Heidenreich PA, Albert NM, Allen LA et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ. Heart Fail. 6(3), 606–619 (2013).
Medline CASGoogle Scholar
45 McRae MP, Bozkurt B, Ballantyne CM et al. Cardiac ScoreCard: a diagnostic multivariate index assay system for predicting a spectrum of cardiovascular disease. Expert Syst. Appl. 15(1), 136–147 (2016).
Google Scholar
46 Elango JK, Gangadharan P, Sumithra S, Kuriakose MA. Trends of head and neck cancers in urban and rural India. Asian Pac. J. Cancer Prev. 7(1), 108–112 (2006).
MedlineGoogle Scholar
47 Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 56(2), 106–130 (2006).
MedlineGoogle Scholar
48 Silverman S Jr. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J. Am. Dent. Assoc. 132(Suppl.), S7–S11 (2001).
Google Scholar
49 Organization WH. mHealth: new horizons for health through mobile technologies: second global survey on eHealth (2011). www.who.int/goe/publications/goe_mhealth_web.pdf.
Google Scholar
50 West D. How mobile devices are transforming healthcare. Issues Technol. Innov. 18(1), 1–11 (2012).
Google Scholar
51 Citron P. Medical devices: lost in regulation. Issues Sci. Technol. 27(3), 23–28 (2011).
Google Scholar
52 Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ. Translational research in cancer genetics: the road less traveled. Public Health Genomics 14(1), 1–8 (2011).
Medline CASGoogle Scholar
53 Huckle D. Point-of-care diagnostics: an advancing sector with nontechnical issues. Expert Rev. Mol. Diagnost. 8(6), 679–688 (2008).
MedlineGoogle Scholar
54 Sinha SR, Barry M. Health technologies and innovation in the global health arena. N. Engl. J. Med. 365(9), 779–782 (2011).
Medline CASGoogle Scholar
55 Floriano PN, Abram T, Taylor L et al. Programmable bio-nanochip-based cytologic testing of oral potentially malignant disorders in Fanconi anemia. Oral Dis. 21(5), 593–601 (2015).
Medline CASGoogle Scholar

Vol. 8, No. 9

Metrics

Downloaded 104 times

History

Published online 13 April 2016

Published in print May 2016

Information

Keywords

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent or reflect views of the NIH or the Federal Government.

Financial & competing interest disclosure

Principal Investigator, JT McDevitt, has an equity interest in SensoDX, LLC, and also serves on the Scientific Advisory Board. Funding was provided by NIH through the National Institute of Dental and Craniofacial Research (NIH Grant No. 3 U01 DE017793-02S1 and 5 U01 DE017793-2). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download